Oseltamivir丨CAS 196618-13-0

Oseltamivir is a widely used antiviral medication primarily employed in the prevention and treatment of influenza A and B infections. It functions as a neuraminidase inhibitor, blocking the viral enzyme responsible for the release of newly formed virus particles from infected host cells. This mechanism helps to halt viral replication and limit the spread of infection within the respiratory tract. Clinically, Oseltamivir is administered as its phosphate salt (oseltamivir phosphate) and is effective when taken early in the course of influenza, typically within 48 hours of symptom onset. It is also prescribed prophylactically to reduce the risk of infection during flu outbreaks or in high-risk populations such as the elderly, immunocompromised patients, and healthcare workers. In pharmaceutical research, Oseltamivir serves as a reference standard in antiviral drug development and testing, supporting studies focused on influenza resistance, pharmacokinetics, and novel antiviral strategies.

Oseltamivir offers significant therapeutic and preventive benefits in managing influenza infections. By inhibiting the neuraminidase enzyme, it effectively reduces the severity and duration of flu symptoms such as fever, sore throat, cough, and fatigue. It also minimizes the risk of complications like pneumonia, bronchitis, and sinusitis, particularly in vulnerable patient groups. Prophylactic use of Oseltamivir has been shown to reduce influenza transmission rates within households and communities. The drug's oral bioavailability and favorable safety profile make it convenient for both adult and pediatric use. Moreover, Oseltamivir's inclusion in global antiviral stockpiles has made it an important component in pandemic preparedness plans, offering a first-line defense against influenza epidemics. Its stable formulation and long shelf life further enhance its utility in public health emergency response systems.